Login / Signup

Long-term surviving cancer patients as a source of therapeutic TCR.

Else Marit InderbergSébastien Wälchli
Published in: Cancer immunology, immunotherapy : CII (2020)
We have established a platform for the isolation of tumour-specific TCR from T cells of patients who experienced clinical benefit from cancer vaccination. In this review we will present the rationale behind this strategy and discuss the advantages of working with "natural" wild type TCRs. Indeed, the general trend in the field has been to use various modifications to enhance the affinity of such therapeutic TCRs. This was done to obtain stronger T cell responses, often at the cost of safety. We further describe antigen targets and recent in vitro and in vivo results obtained to validate them. We finally discuss the use of MHC class II-restricted TCR in immunotherapy. Typically cellular anti-tumour immune responses have been attributed to CD8 T cells; however, we isolated mainly CD4 T cells. Importantly, these MHC class II-restricted TCRs have the potential to induce broad, long lasting immune responses that enable cancer control. The use of CD4 T cell-derived TCRs for adoptive immunotherapy has so far been limited and we will here discuss their therapeutic potential.
Keyphrases
  • immune response
  • papillary thyroid
  • regulatory t cells
  • wild type
  • squamous cell
  • cell therapy
  • lymph node metastasis
  • clinical trial
  • toll like receptor
  • high throughput
  • risk assessment
  • bone marrow
  • mass spectrometry